社区药剂师对药物基因组学服务的知识,态度,感知和自我报告的信心
Usman Abubakar1, Lienarrubini Subramaniam2, Amer Hayat Khan2
1Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Journal of pharmaceutical policy and practice
|October 6, 2025
概括
社区药剂师对药物基因组学服务的知识和信心很低,尽管人们对药物基因组学服务的看法很好. 药物基因组学培训对于提高他们的技能和对优化患者药物治疗的信心至关重要.
科学领域:
- 药物基因组学及其在优化患者药物治疗中的应用.
- 社区药剂师在药物基因组学实施中的新兴作用.
背景情况:
- 药物基因组学越来越多地被用于个性化药物治疗,以改善患者的治疗结果.
- 社区药剂师在不断扩大的药物基因组学服务领域中起着关键作用.
研究的目的:
- 评估社区药剂师对药物基因组学服务的知识,态度,感知和信心.
- 在社区药房设置中识别药物基因组学的实施障碍.
主要方法:
- 一项涉及马来西亚城社区药剂师的横截面研究.
- 从2022年3月至4月通过自我管理,验证的问卷收集的数据.
- 使用了描述性和推断性的统计分析.
主要成果:
- 观察到知识低 (中位数9.0/16) 和自我报告的信心低 (中位数23/40).
- 以前的药物基因组学培训和对未来培训的兴趣与更高的知识和信心分数相关.
- 发现的主要障碍包括缺乏知识 (84.5%),指导方针 (83.6%) 和报销 (75.4%).
结论:
- 社区药剂师在有关药物遗传学服务的知识和信心方面表现出缺陷.
- 建议针对性培训,制定地方指导方针和报销策略,以确保成功实施.
相关概念视频
Analysis of Population Pharmacokinetic Data
677
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
677
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Biopharmaceutics and Pharmacokinetics: Overview
3.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.3K
Dosage Regimens: Partial Pharmacokinetic Parameters
150
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
150
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
180
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
180
Factors Affecting Protein-Drug Binding: Patient-Related Factors
305
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
305


